logo

Auris Medical Holding Ag (EARS)



Trade EARS now with
  Date
  Headline
1/4/2018 8:30:30 AM Auris Medical Says HEALOS Trial Not Met Primary Efficacy Endpoint In Overall Study Population
11/28/2017 6:42:30 AM Auris Medical Q3 Net Loss CHF 6.0 Mln Or CHF 0.14/Shr Vs CHF 7.9 Mln Or CHF 0.23/Shr Last Year
11/28/2017 6:41:20 AM Auris Medical Reports Top-Line Results From Phase 3 Trial Of AM-111 In Sudden Deafness
10/11/2017 6:47:46 AM Auris Medical Executes Two Share Purchase Agreements For Up To $15.0 Mln With Lincoln Park Capital Fund, LLC
9/22/2017 8:03:25 AM Auris Medical Completes Patient Recruitment For Phase 3 TACTT3 Trial Of Keyzilen® In Acute And Post-Acute Tinnitus
8/10/2017 6:40:12 AM Auris Medical Q2 Net Loss CHF 5.4 Million, Or CHF 0.12/shr Vs. Loss CHF 8.4 Mln Or CHF 0.25/shr Prior Year
7/20/2017 8:06:18 AM Auris Medical Completes Acquisition Of Various Assets Related To Intranasal Betahistine From Otifex Therapeutics
7/5/2017 8:03:14 AM Auris Medical Completes Enrollment Of Phase 3 HEALOS Trial Of AM-111 For Treatment Of Sudden Deafness
5/11/2017 6:17:49 AM Auris Medical Q1 Net Loss CHF 8.4 Mln Or CHF 0.22/shr Vs Loss CHF 8.9 Mln Or CHF 0.26/shr Last Year
3/14/2017 6:10:52 AM Auris Medical 2016 Net Loss CHF 30.7 Mln Or CHF 0.89/Shr Vs Loss CHF 29.7 Mln Or CHF 0.92/Shr Last Year
2/24/2017 8:04:42 AM Auris Medical Says FDA Granted Fast Track Designation For AM-111 In Treatment Of Acute Sensorineural Hearing Loss